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Regadenoson: A New Myocardial Stress Agent
Wael Al Jaroudi, MD, Ami E. Iskandrian, MD
Birmingham, Alabama
Vasodilator stress myocardial perfusion imaging (MPI) accounts for up to 50% of all stress MPI studies per-
formed in the U.S. In 2008, the Food and Drug Administration approved regadenoson for stress testing in con-
junction with MPI. Regadenoson, unlike adenosine, is a selective A2A agonist that is given as an intravenous bo-
lus at a fixed dose, with less undesirable side effects including atrioventricular block and bronchospasm. Unlike
adenosine, regadenoson could be used in patients with mild-to-moderate reactive airway disease. This review
will summarize the pre-clinical and clinical data on regadenoson, as they specifically relate to its use as a vaso-
dilator stress agent, currently the only approved selective A
2A
agonist. (J Am Coll Cardiol 2009;54:1123–30)
© 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.089A
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doronary artery disease accounts for 20% of the deaths in
he U.S. (1). Myocardial perfusion imaging (MPI) is widely
sed for the detection of coronary artery disease, risk
ssessment, detection of viable myocardium, and evaluation
f the effects of various therapeutic interventions (2).
At present, up to 50% of MPI studies are performed with
asodilators rather than with exercise (3). Adenosine and
ipyridamole have been the mainstays of vasodilator stress
esting for almost 2 decades since the approval by the Food
nd Drug Administration (FDA) of adenosine (Adenoscan,
lfa Aesar, Ward Hill, Massachusetts) in 1990. Dobut-
mine stress MPI is reserved for patients with contraindi-
ations for vasodilator testing (5% of patients). Adenosine
riphosphate is approved in Japan but not in the U.S. (2). In
he past few years, several selective A2A agonists have been
xamined as potential stress agents, and regadenoson
Lexiscan, Gilead Sciences Inc., Foster City, California) is
he first one to be approved by the FDA. This review will
ummarize its current status and unique features in com-
arison with adenosine, which is a nonselective agonist.
denosine
he production and metabolism of adenosine have been
xtensively reviewed elsewhere and will not be discussed
ere (2,4,5). Adenosine nonselectively activates 4 receptor
ubtypes: A1, A2A, A2B, and A3. Activation of the Gi/o
rotein-bound A1 and A3 receptors reduces adenylyl cyclase
ctivity and decreases intracellular cyclic adenosine mono-
hosphate. However, activation of the Gs protein-bound
rom the Division of Cardiovascular Diseases, Department of Medicine, The
niversity of Alabama at Birmingham, Birmingham, Alabama. Dr. Iskandrian was
he Chair of the International Phase 3 trials on Regadenoson and is a consultant to
V Therapeutics and to Astellas Pharma US, Inc., Deerfield, Illinois.s
Manuscript received January 22, 2009; revised manuscript received March 10,
009, accepted April 26, 2009.2A and A2B receptors increases adenylyl cyclase activity
nd cyclic adenosine monophosphate levels (6).
Activation of cardiac A2A and A2B adenosine receptors
asodilates the coronary and peripheral arterial beds, in-
reases myocardial blood flow (MBF), and causes sympa-
hoexcitation. Activation of cardiac A1 receptors mediates
he negative chronotropic, dromotropic, inotropic, and anti-
eta-adrenergic effects. Stimulation of A3 and A2B receptors
roduces mast cell degranulation and bronchial constriction
7,8). The discovery of the various subtypes of adenosine
eceptors has paved the way for therapeutic potential of
elective antagonists and agonists (9,10).
The use of adenosine for stress MPI is primarily related
o the activation of A2A receptors and the resultant increase
n MBF; the activation of A1, A2B, and A3 receptors
roduces short-term undesirable side effects. Furthermore,
he very short half-life of adenosine necessitates a continu-
us intravenous infusion.
Regadenoson is the first selective A2A receptor agonist
hat is approved by the FDA and is currently used clinically.
t has many of the characteristics of an ideal stress perfusion
gent, being a potent and a selective coronary vasodilator
ith a rapid onset of action, a short duration of action, and
eing administered as a fixed-dose bolus (not weight-
ased). Further, it has a good safety and tolerability profile
ncluding in patients with reactive airway disease, and finally
ts side effects can be readily reversed by an antagonist if
eeded (11–13).
tructure and Synthesis
he structural modification of adenosine derivatives pro-
ides different plasma stability, lipophilicity, and selective
ffinity for receptor subtypes. The 4-substituted pyrazole
erivative (regadenoson) gives the molecule its highly
elective A2A receptor-binding properties (14,15).
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Use of Regadenoson in Stress Testing September 22, 2009:1123–30Regadenoson is a 2-[N-1-(4-N-
methylcarboxamidopyrazolyl)]-
adenosine derivative. It is syn-
thesized from the condensation of
2-hydrazino-adenosine with eth-
oxycarbonylmalondialdehyde fol-
lowed by aminolysis with methyl-
amine, or from 2-cholo or 2-iodo
adenosine derivatives (15) (Fig. 1).
Receptor Affinity
The selectivity of regadenoson
was established in radioligand
binding assays and was found to
have low affinity for A1, A2B, and
A3 adenosine receptors (16).
rochu et al. (17) further showed in an animal model the
ack of A1 response in contradistinction to a dose-dependent
2A response. Regadenoson was also shown to have absent
ronchoconstrictive response in control and allergen-
ensitized mice (18).
By design, regadenoson has a low affinity for the A2A
denosine receptor. Affinity (Ki) is defined as the ratio of
he rate of drug dissociation to the rate of drug association
o the receptor (16). Because of the large A2A receptor
eserve in the coronary arterial bed, an ideal selective A2A
eceptor agonist may have a relatively low binding affinity
ithout affecting the maximal coronary vasodilation (19).
rugs with low affinity (high Ki) have a shorter duration of
ffect than drugs with high affinity. For example, the Ki
alue of adenosine is 2,700 to 5,600 while that of regade-
oson is 1,200 (16).
The low affinity of a selective A2A agonist in a large
eceptor reserve bed allows maximal vasodilation effect and
apid termination of action. The time required in reversing
Figure 1 Chemical Structures of Adenosine and Regadenoson
MW  molecular weight.
Abbreviations
and Acronyms
COPD  chronic
obstructive pulmonary
disease
FDA  Food and Drug
Administration
FEV1  forced expiratory
volume (1 s)
LV  left ventricle/
ventricular
MBF  myocardial blood
flow
MPI  myocardial perfusion
imaginghaximal increase of coronary conductance by 50% by
denosine and regadenoson was 1.6 and 5.2 min, respec-
ively. Possibly other factors such as dose, metabolism, and
olume of distribution also affect duration of action (16). Of
ote, the duration of action is at times defined in different
ays such as how long a response exceeds some arbitrary
hreshold of peak MBF (i.e., 2  resting flow) and not
ecessarily the time to return to baseline MBF.
oronary Vasodilator Properties
n a dog model, intravenous bolus injection of regadenoson
aused a dose-dependent increase in MBF comparable to
hat produced by adenosine infusion. Both drugs caused a
ose-dependant decrease in coronary vascular resistance
maximal decrease of 73% by both). The maximal increase
n MBF with regadenoson (2.5 g/kg intravenous bolus)
as approximately 84% of the peak MBF achieved by
ransient occlusion of the coronary artery. The increased
BF after bolus of regadenoson remained at least 2-fold
bove the baseline for 97 s as compared with 24 s with
denosine (267 g/kg) (p  0.01) (17).
Zhao et al. (20) showed similar data in a dog animal model;
egadenoson and adenosine caused a dose-dependent increase
nMBF, with nonstatistically different maximal values between
he 2 drugs although regadenoson was 100more potent than
denosine (ED50  0.45 vs. 47 g/kg, respectively).
emodynamic Effects
rochu et al. (17) used a solid-state pressure gauge in the
eft ventricular (LV) apex to measure the LV systolic
ressure and its first derivative (LV dP/dt) during regade-
oson and adenosine infusion. Regadenoson did not cause
hanges in the LV systolic pressure, while adenosine in-
reased it by 12% and 18% at doses of 134 and 267 g/kg,
espectively. However, both regadenoson and adenosine
ncreased LV dP/dt by 39% and 29%, respectively. Further-
ore, the increase in heart rate and duration of the increase
ere greater with regadenoson than adenosine. The de-
reases in mean arterial blood pressure were 13 mm Hg and
8 mm Hg with regadenoson and adenosine, respectively
17). Similarly, the decrease in systemic vascular resistance
as less with regadenoson than adenosine (Fig. 2). Neither
rug caused a significant change in cardiac output (20).
Unlike adenosine, which caused a dose-dependent renal
asoconstriction at a 250-g/kg dose (683  197% increase
n renal vascular resistance, and an 85  4% decrease in
enal blood flow), regadenoson (2.5 g/kg) did not affect
enal vascular resistance and caused a mild decrease in renal
lood flow (11  4%) (20). Aminophylline (20 mg/kg)
dministration prevented the coronary and systemic hemo-
ynamic effects of 1 g/kg of regadenoson and significantly
educed the effect of the higher dose of the drug (2.5 g/kg)
17). In the phase 3 trials, aminophylline was seldom used
ith either adenosine or regadenoson. In clinical use, there
as seldom been a need for aminophylline use in our
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September 22, 2009:1123–30 Use of Regadenoson in Stress Testingxperience to counteract undesirable side effects of regade-
oson. In a dog animal model, caffeine did not affect the
aximal MBF but decreased the duration of hyperemia
rom 8.6 1.2 min to 1.5  0.4 min (21).
The mechanism of regadenoson-mediated tachycardia
as further investigated by Dhalla et al. (22). In a rat heart
odel, regadenoson was shown to have a dose-dependent
ncrease in heart rate and a decrease in mean arterial
ressure at the higher doses. These changes were abolished
sing a selective A2A antagonist. Pre-treatment with a
eta-blocker reduced the tachycardia but not the hypoten-
ion, while pre-treatment with a ganglion blocker prevented
he tachycardia but not the transient hypotension. Regade-
oson also caused more than a 2-fold increase in serum
orepinephrine and epinephrine. These results suggested
hat the A2A receptor-mediated sinus tachycardia is mainly
ue to direct sympathoexcitation rather than being barore-
ex mediated (22). A study conducted by Hage et al. (23)
howed that the increase in heart rate by either adenosine or
egadenoson was significantly blunted in diabetic than
ondiabetic patients, possibly due sympathetic denervation
n diabetic patients, hence reinforcing the sympathoexcita-
ion mechanism (23).
linical Data
egadenoson has a volume of distribution of 11.5 l and
8.7 l (at steady-state), and an estimated clearance of 37.8
/h. It is renally excreted (58% of total elimination) with a
erminal half-life of 33 to 108 min. Gordi et al. (24) showed
hat the lack of a correlation between the model estimates
nd various baseline patient demographics supports unit-
ased dose administration of regadenoson. There is no need
Figure 2 Comparison of Regadenoson Versus
Adenosine on Vascular Resistance in Dogs
Regadenoson caused a smaller decrease in systemic vascular resistance com-
pared with adenosine. Both drugs reduced mesenteric vascular resistance to
the same extent. *p  0.05. The error bars represent the standard error of
the means.o adjust the dose in patients with renal failure, as there were
co adverse effects in patients with serum creatinine clearance
f 30 ml/min after administration of a 400-g regadeno-
on intravenous bolus (26). The pharmacokinetic and phar-
acodynamic properties of regadenoson are summarized in
able 1 (2,24–26).
In 38 volunteer subjects, flow velocity (measured by
ntracoronary Doppler-tipped guidewire) increased more
han 3-fold with 300-, 400-, and 500-g bolus doses of
egadenoson (26). The mean time to peak effect was 33 s (20
o 40 s); the durations of the increase in flow velocity greater
han 2.5 the baseline were 2.3 and 2.4 min with the 400-
nd 500-g doses, respectively. Aminophylline, a compet-
tive inhibitor of adenosine, reversed the effect of regadeno-
on and reduced the coronary hyperemia duration (2-fold
ncrease in MBF) from 6.9 to 0.6 min (26) (Fig. 3).
Similar to the animal data, in a study using positron
mission tomography to measure MBF in human volun-
eers, moderate caffeine consumption did not affect the
aximal MBF (2.98  0.14 ml/min/g vs. 3.05  0.14
l/min/g) or the coronary flow reserve (2.75 0.16 vs. 2.97 
.16, p  NS) (27). The duration of maximum hyperemia
as not evaluated. The clinical results of masking isch-
mia by caffeine with adenosine have been inconsistent
28,29). Several other studies have examined the effects of
affeine on MBF (30), but it should be noted that effects
f adenosine or regadenoson on MBF might be different
rom those on perfusion because of the nonlinear rela-
ionship between peak MBF and tracer concentration in
he myocardium (2).
PI Using Regadenoson
phase 2 trial enrolled 36 patients who had reversible
schemia on adenosine MPI. The patients then had a repeat
PI with either 400- or 500-g regadenoson given as an
ntravenous bolus. Images, interpreted by 3 blinded readers,
ad 89% and 76% agreement rates for the presence of
omparison of Adenosine and Regadenosonharmacokinetic a d Pharmacodynamic Propertiesn Human Volunte rs
Table 1
Compariso of Adenosin and Regadenoson
Pharmacokinetic and Pharmacodynamic Properties
in Human Volunteers
Adenosine Regadenoson
Formula C10H13N5O4 C15H18N8O5.H2O
Molecular weight (g/mol) 267.24 408.37
Mode of action Nonselective agonist Selective A2A agonist
Administration Infusion IV bolus
Dose 140 g/kg/min 400 g
Duration of infusion 4–6 min 10-s bolus
Radiotracer injection Third minute of infusion 30 s after bolus
Terminal half-life 2–10 s 33–108 min
Time to peak 30 s 33 s
Duration of action 6 s* 2.3 min†
Elimination Cellular uptake Renal (57%)
Antidote Aminophylline Aminophylline
Because adenosine is administered as an infusion, the duration of action is as long as the duration
f the infusion; therefore, the 6-s value is misleading; †duration of action is defined as duration of
oronary blood flow 2.5  baseline.
IV  intravenous.
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Use of Regadenoson in Stress Testing September 22, 2009:1123–30schemia with the 400- and 500-g doses, respectively, com-
ared with adenosine images.When patients were divided into
groups based on summed stress score (the score is based on
17-segment model where each segment is scored on a scale of
to 4, where 0 normal tracer activity and 4 absent tracer
ctivity) (0 to 3, 4 to 7, 8 to 11), the agreement rates between
egadenoson and adenosine were 57% and 69% by visual and
uantitative analysis, respectively (31).
The pivotal phase 3 trials that culminated in the FDA
pproval of this drug were 2 identical randomized, doubled-
lind studies of over 2,000 patients in more than 100 sites
32,33). The patients had a baseline adenosine MPI and
ere then randomized in a 2:1 ratio to regadenoson
400-g intravenous bolus in 10 s) and adenosine. Be-
ause there was no reason to expect the results with
egadenoson to be superior to those with adenosine, the
rials were designed as noninferiority studies (34,35).
The primary end point was to demonstrate that the
ifference between sequential adenosine–regadenoson im-
ges and adenosine–adenosine images, based on blinded
eading, lay above a pre-specified noninferiority margin.
he images were processed in a central core laboratory and
nterpreted by 3 blinded readers. The quality of the images
as comparable; good or excellent in 88% to 90% of patients
iven either drug (Fig. 4).
The average agreement rate was 0.62 0.03 for adenosine–
denosine and 0.63 0.02 for adenosine–regadenoson images;
he difference was above the lower limit of the 95% confidence
nterval in the entire group of patients as well as in pre-
pecified subgroups based on age, sex, body weight, and
Figure 3 Effect of Aminophylline Infusion on Regadenoson-Med
Aminophylline injection (100 mg) did not affect the peak-to-baseline coronary flow
(CFVR) ratio, but significantly blunted the duration of hyperemia (2-fold increase iniabetes. Further, side-by-side image interpretation showed comparable agreement rates between the adenosine and rega-
enoson groups (0.76 0.03 vs. 0.77 0.02 and 0.77 0.02
s. 0.78  0.02) for the presence and absence of ischemia,
espectively (33). The problems associated with agreement
ates by visual analysis have been previously addressed.
nalysis of the same data by automated quantitative analysis
howed 90% agreement rates for adenosine–adenosine as
ell as adenosine–regadenoson images (36).
hanges in Heart Rate and Blood Pressure
egadenoson, like adenosine, produces a decrease in blood
ressure and an increase in heart rate. The effects of
egadenoson and adenosine to decrease the blood pressure
ere not significantly different. The heart rate response was
igher with regadenoson than adenosine (32,33) (Fig. 5).
he mechanism of the increase in heart rate was discussed
arlier (22,23).
afety and Adverse Events
he side effects of regadenoson observed in the phase 3 clinical
rials are summarized in Table 2 (33). They were mild and
ransient in nature; none was life threatening or serious. There
ere no instances of high-degree atrioventricular block. How-
ver, patients who had atrioventricular block on entry MPI
ere excluded from the study. There were no reported deaths
r life-threatening arrhythmias. There was no QT prolon-
ation consistent with earlier animal data (37). Regade-
oson was preferred over adenosine, based on patient
atisfaction scores; the summed score due to flushing,
Coronary Vasodilation in Human Volunteers
y reserve
above baseline). *p  0.05.iated
velocit
CFVRhest pains, and dyspnea (the 3 most common side effects
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September 22, 2009:1123–30 Use of Regadenoson in Stress Testingith adenosine) was lower with regadenoson than with
denosine in the entire group of patients as well as in
omen and the elderly (32,33) (Fig. 6). The combination
f low-level exercise with regadenoson has been shown in
small study to reduce the side effects (38).
tudies in Patients With Asthma
nd Chronic Obstructive Lung Disease
denosine might provoke bronchospasm in certain suscep-
ible patients such as those with asthma or those on
Figure 4 Regadenoson/Rest SPECT Images Showing a Large R
Perfusion Abnormality in the Inferior and Lateral Segm
By quantitative analysis, the abnormality involved 29% of the myocardium. The pat
54-year-old man with chest pains. LV  left ventricular; SPECT  single-photon em
Figure 5 Changes in HR and Blood Pressure With Regadenoson
Regadenoson bolus administration caused a greater increase in maximal heart rat
regadenoson and adenosine on systolic and diastolic blood pressure (BP) were noaintenance doses of bronchodilators or steroids. The
electivity of regadenoson was therefore of great interest to
tudy for its safety and efficacy in such patients. The final
nswer is not yet in, and more studies are needed, but there
re some preliminary data.
Prior studies have suggested that with prophylactic pre-
reatment with a B-2 agonist, adenosine could be given to
atients with mild asthma or chronic obstructive lung
isease (COPD). It should be noted the majority of patients
ith COPD but no bronchospasm could be tested with
sible
of the LV Myocardium
a
computed tomography.
sus Adenosine
than did an adenosine infusion (*p  0.05). Effects of
stically different. The error bars represent standard error of the mean.ever
ents
ient is
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Use of Regadenoson in Stress Testing September 22, 2009:1123–30denosine without any serious problem (39). Further, tachy-
nea is common after adenosine infusion and is not due to
hanges in airway resistance or pulmonary capillary wedge
ressure but rather to stimulation of carotid body receptors
40,41).
A randomized double-blind, placebo-controlled cross-
ver trial assessed the safety of regadenoson in 48 patients
ith proven mild (n  24) or moderate (n  24) asthma
positive challenge test) based on the global initiative for
sthma guidelines (42). There was at least a 6-h abstention
rom the use of bronchodilators before the study. A dose of
00-g regadenoson or a matching placebo was infused
ver 10 s. The mean forced expiratory volume at 1 s (FEV1)
t any time point was not statistically different between
lacebo and regadenoson-treated patients. Similarly, the
ncidence of bronchospasm was 4% in both groups (p 
.99). No patient had oxygen desaturation (92%) in either
roup. More patients experienced dyspnea with regadeno-
on than with placebo (43), although this was not associated
ith a decrease in FEV1.
A similar double-blind, cross-over study enrolled 49
atients (mean age 67 years) with moderate (stage II) or
Figure 6 Summed Symptom Score With Regadenoson and Aden
The mean summed symptom score for chest pain, dyspnea, and flushing, and the
versus adenosine groups (*p  0.05). The score for each symptom was calculate
dard error of the mean.
dverse Event Incidence of Regadenoson in All Patients and in SpeEld ly, Women, Obese, and Patients With Diabetes)Table 2 Adverse Ev nt Incidence of Regadenoson in All Patien(Elderly, Women, Obese, and Patients With Diabetes)
Any Event Chest Pain Dyspnea
All patients 73% 29% 28%
Elderly (65 yrs) 72% 26% 27%
Women 80% 36% 31%
BMI 30 kg/m2 73% 28% 29%
Patients with diabetes 73% 29% 24%
MI  body mass index; GI  gastrointestinal.evere (stage III) COPD (based on the Global Initiative for
hronic Obstructive Lung Disease Scientific Committee
riteria) (44). Patients were randomized to 400-g regade-
oson/placebo sequence or placebo/400-g regadenoson.
atients received their regular daily COPD medications
xcept bronchodilators, which were withheld for at least 8 h
efore the study. Measurements included FEV1, forced vital
apacity, and pulse oximetry in addition to pulmonary
hysical examination.
There were no statistically significant differences in values
f mean FEV1 and forced vital capacity, mean oxygen
aturation, bronchoconstriction, and new-onset wheezing at
ny time between groups. Dyspnea, however, was more
ommon in the regadenoson group but was not related to a
ecline in FEV1 or any objective finding (45).
These results suggest that regadenoson could be safely
dministered to patients with mild or moderate reactive
irway disease. There is no comparable data on adenosine
nfusion in patients with moderate-to-severe asthma as this
rug is contraindicated in this population. However, a larger
nd more definitive multisite study is needed to clearly
efine the safety of regadenoson use in patients with
e
summed score of all the symptoms were significantly lower in the regadenoson
, absent; 1, mild; 2, moderate; and 3, severe. The error bars represent stan-
Groupsd in Special Groups
ushing Headache GI Dizziness Neck/Jaw Pain
22% 23% 23% 8% 7%
21% 24% 24% 7% 7%
17% 37% 32% 7% 9%
23% 27% 22% 7% 6%
22% 25% 25% 6% 5%osin
mean
d as: 0cialts n
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September 22, 2009:1123–30 Use of Regadenoson in Stress Testingheezing and in patients on maintenance doses of broncho-
ilators and/or steroids.
egadenoson Market
ince the FDA approval of regadenoson on April 2008, the
arket share has increased steadily (2% in July 2008 vs. 11%
n November 2008) together with a decline in the use of
denosine and no change in the use of dipyridamole. By
ctober 2008, the market share of regadenoson has sur-
assed that of dobutamine (11% vs. 7%) (46). At present,
he cost of regadenoson is slightly lower than adenosine, but
hat may change once adenosine becomes generic.
ummary and Future Perspectives
egadenoson has appealing features for clinical use, ease of
dministration as a bolus, weight-unadjusted dose, a fast
nset and short duration of action, sufficient hyperemic
esponse, and comparable efficacy to adenosine but with less
ide effects. Unlike adenosine, regadenoson could also be
sed in patients with mild-to-moderate reactive airway
isease and obstructive lung disease. The cost must be
onsidered especially after a generic form of adenosine
ecomes available. These features are likely to expand the
se of these agents beyond MPI to stress testing with other
maging modalities and to measure coronary hemodynamics
n the cardiac catheterization laboratory with the flow-
oppler catheter (47). There are 2 other selective A2A
gonists at various stages of development: 1 completed
hase 3 trials (binodenoson, MRE0470, King Pharma,
ristol, Tennessee) and the other is about to start large-scale
tudies (apadenoson, ATL146e, PgXHealth, LLC, a divi-
ion of Clinical Data, Inc., Newton, Massachusetts)
48,49). We have no data comparing these new agents at
resent.
eprint requests and correspondence: Dr. Wael Al Jaroudi, 701
9th Street, LHRB 306, Birmingham, Alabama 35294. E-mail:
aljaroudi@cardmail.dom.uab.edu.
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